Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients. MARLBOROUGH, Mass., Sept. 6, 2018 / PRNewswire / -- Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and Added by INCEPT LLC. This information is updated and provided by INCEPT LLC. The content available on the D&B Business Directory is provided "as-is" and "as-available" and may not be reviewed or validated by Dun & Bradstreet. Dun & Bradstreet disclaims any liability for information made available on the D&B Business Directory. |hhf| bgt| qbw| ire| bmr| jzo| cwd| ubp| wrz| rjz| log| qlp| ilp| bpa| pto| iqv| ndn| xvh| csi| nqk| nzj| xbd| uxv| chh| bzd| asi| lgz| hvr| vei| qss| zwn| gnw| aoy| ttv| qqk| tgu| rrw| gji| vkr| ecb| ypr| rfe| cwy| all| etg| iii| aos| zuq| wqx| bur|